The interaction of sodium nitroprusside with human endothelial cells and platelets: nitroprusside and prostacyclin synergistically inhibit platelet function.
Sodium nitroprusside (NP) is a potent vasodilator that also inhibits platelet aggregation. To test the hypothesis that NP causes both of these effects by altering the balance between prostacyclin (PGI2) produced by endothelial cells and thromboxane A2 (TXA2) produced by platelets, we incubated each of these cell types with NP for 5 minutes and assayed the PGI2 and TXA2 produced. NP at pharmacologically achieved doses (0.01--30 micrograms/ml) inhibited platelet aggregation and resultant TXA2 synthesis in a dose- and time-dependent manner (p less than 0.001). The inhibition was not dependent on cAMP production, external calcium concentration, or suppression of TXA2 synthesis. NP did not alter the production of PGI2 by cultured human endothelial cells as measured by radioimmunoassay for 6-Keto-PGF1 alpha, the stable hydrolysis product of PGI2. However, supernates of NP-treated endothelial cells containing low, noninhibitory concentrations of NP unexpectedly inhibited platelet aggregation. This inhibition of platelet aggregation was due to synergy between PGI2 (0.1--3 nM) and NP (p interaction less than 0.03). The synergistic inhibition by NP and PGI2 of platelet aggregation and TXA2 synthesis in vivo may explain some of the beneficial actions of NP in the treatment of hypertension and congestive heart failure.
D002118:Calcium / Q000097:blood; D002463:Cell Membrane Permeability / Q000187:drug effects; D003078:Colchicine / Q000494:pharmacology; D000242:Cyclic AMP / Q000097:blood; D003864:Depression, Chemical; D003903:Deuterium / Q000494:pharmacology; D017666:Deuterium Oxide; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004727:Endothelium / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D011464:Epoprostenol / Q000494:pharmacology*; D005292:Ferricyanides / Q000494:pharmacology*; D006801:Humans; D009599:Nitroprusside / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D011453:Prostaglandins / Q000494:pharmacology*; D013928:Thromboxane A2 / Q000096:biosynthesis; D014867:Water / Q000494:pharmacology
D005292:Ferricyanides; D011453:Prostaglandins; D014867:Water; D009599:Nitroprusside; D013928:Thromboxane A2; D003903:Deuterium; D011464:Epoprostenol; D000242:Cyclic AMP; D017666:Deuterium Oxide; D003078:Colchicine; D002118:Calcium